Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab

Patients harboring EGFR exon 20 insertion (EGFRex20ins) advanced Non-Small Cell Lung Cancer (NSCLC) represent a poor prognosis population of oncogene-addicted cancers in need of targeted therapy, since they are resistant to available EGFR tyrosine kinase inhibitor (TKIs) and there is limited efficacy data of immunotherapy. New drugs targeting EGFRex20ins are under development, such as mobocertinib, an antiEGFR TKI or amivantamab, a bispecific antibody targeting EGFR and MET, which have shown promising results in pre-treated patients. The activity of mobocertinib after treatment with amivantamab and vice versa is currently unknown. We present a 49-year-old, non-smoking woman with advanced EGFRex20ins NSCLC who had a significant response to mobocertinib after several treatments, including amivantamab. We discuss new treatments in development for patients with EGFRex20ins NSCLC.